---
title: "Amgen, Inc v Sanofi-Aventis Deutschland GmbH and others (UPC CoA 528/2024, 25-11-2025)"
description: "The Court of Appeal overturned the Munich central division and upheld Amgen's PCSK9 antibody patent EP 3 666 797 against Sanofi and Regeneron, finding that the…"
url: https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2025-11-25
lang: en
author: "UPC Case Law by Pitch"
editor: "Bart Lieben"
datePublished: 2026-11-18T10:07:28.153Z
dateModified: 2026-11-18T10:07:28.153Z
---

# Amgen, Inc v Sanofi-Aventis Deutschland GmbH and others

Decision of the UPC Court of Appeal of 25 November 2025, UPC CoA 528/2024.

UPC Case Law by Pitch, edited by [Bart Lieben](https://pitch.law/team/bart-lieben) · Published 18-11-2026

## TL;DR

The Court of Appeal overturned the Munich central division and upheld Amgen's PCSK9 antibody patent EP 3 666 797 against Sanofi and Regeneron, finding that the skilled person had no reasonable expectation of success that an antibody would be therapeutically effective. In doing so, the Court set out the UPC's own framework for inventive step, including the rule that the skilled person "would", not merely "could", have arrived at the invention, and who bears the burden of proof on expectation of success.

## Key holding

Under Art 56 EPC, a claimed solution is obvious only if the skilled person, starting from a realistic starting point, would (and not only could) have reached it, typically because the result was clearly predictable or there was a reasonable expectation of success. The party asserting invalidity bears the burden of proving that expectation. Once the patentee substantiates uncertainties or practical difficulties, that party must also prove these would not have prevented a reasonable expectation of success. In a medical use claim, therapeutic efficacy is an inherent feature requiring a noticeable (meaningful) improvement of the patient's condition, not merely any measurable effect.

## Questions decided

1. What is the UPC test for inventive step, including reasonable expectation of success?
2. Who bears the burden of proof on reasonable expectation of success?
3. What level of therapeutic effect does a medical use claim implicitly require?
4. Can dependent claims adding a separate feature inform interpretation of the main claim?
5. May the Court examine the whole application when assessing added matter, regardless of the passages the parties cited?
6. Does a functional antibody claim lack sufficiency because not every embodiment is enabled?

## Case details

- Court: Court of Appeal of the Unified Patent Court, Panel 2
- Panel: Rian Kalden (presiding judge and judge-rapporteur); Patricia Rombach (legally qualified judge); Ingeborg Simonsson (legally qualified judge); Rainer Friedrich (technically qualified judge); Cornelis Schüller (technically qualified judge)
- Date: 25-11-2025
- Case number(s): UPC CoA 528/2024, UPC CoA 529/2024, UPC CFI 1/2023, UPC CFI 14/2023
- Parties: Appellant: Amgen, Inc (defendant at first instance). Respondents: Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A. and Sanofi Winthrop Industrie S.A. (claimants in the revocation action), and Regeneron Pharmaceuticals Inc. (counterclaimant for revocation).
- Language of the proceedings: English
- Outcome: In both appeals the Court of Appeal set aside the impugned decision and rejected the requests to revoke the patent in the Territories.

## How to cite

Court of Appeal, Amgen, Inc v Sanofi-Aventis Deutschland GmbH and others, UPC CoA 528/2024, UPC CoA 529/2024, Decision of 25 November 2025 (OSCOLA)

## Full summary

Read the full analyses for free — create a free account: https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2025-11-25

Topics: [Validity and revocation](https://pitch.law/academy/upc-court-of-appeal/topics/validity)

## In the same case

- [Sanofi-Aventis Deutschland GmbH and others v Amgen, Inc, UPC CoA 528/2024, 25-03-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2026-03-25): The Court of Appeal allowed Sanofi and Regeneron to withdraw their applications for rehearing of its November 2025 decision upholding Amgen's patent EP 3 666 797, and declared the proceedings closed.
- [Petition for review of a decision of the Registrar (EPLC Rules, Rule 12.1), anonymised applicant, UPC CFI 1/2023, 26-01-2026](https://pitch.law/academy/upc-court-of-appeal/upc-cfi-1-2023-2026-01-26): The President of the UPC Court of Appeal upheld the Registrar's refusal to enter a European Patent Attorney on the list of UPC representatives, because he relied on a Rule 12.1 EPLC Rules course but applied in August 2025, after the one-year transitional period had expired on 3 June 2024.
- [Microsoft Corporation v Suinno Mobile & AI Technologies Licensing Oy, UPC CoA 826/2024, 23-12-2024](https://pitch.law/academy/upc-court-of-appeal/upc-coa-826-2024-2024-12-23): The Court of Appeal's standing judge refused to review a Central Division order that let a patentee unconditionally cut the damages it claims from Microsoft.
- [Panasonic Holdings Corporation v Xiaomi Technology Germany GmbH and others, UPC CoA 86/2024, 05-08-2024](https://pitch.law/academy/upc-court-of-appeal/upc-coa-86-2024-2024-08-05): A claimant at the UPC cannot serve a statement of claim on Chinese and Hong Kong defendants simply by delivering it to their German group company.
- [Sanofi-Aventis Deutschland GmbH and others v Amgen Inc., UPC CoA 320/2023, 13-10-2023](https://pitch.law/academy/upc-court-of-appeal/upc-coa-320-2023-2023-10-13): A statement of claim can be validly served without its annexes, so the deadlines for the preliminary objection and the statement of defence run from service.

## More on validity and revocation

- [Netflix Services Germany GmbH and others v DivX, LLC, UPC CoA 176/2026, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-176-2026-2026-11-02): The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.
- [Appellant (name not stated) v Amycel, LLC, UPC CoA 935/2025, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-935-2025-2026-11-02): The Court of Appeal set aside a decision by default of The Hague Local Division and allowed the defendant's application to have it set aside under R 356 RoP.
- [Barco N.V. v Yealink (Xiamen) Network Technology Co., Ltd. and others, UPC CoA 145/2026, 16-10-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-145-2026-2026-10-16): The Court of Appeal upheld the Brussels Local Division's refusal to let Barco add a late auxiliary request (AR6) whose claim 1 is identical to dependent claim 9, a claim neither asserted for infringement nor attacked in the counterclaim for revocation.
